NXSNext Science
About Next Science
Next Science (ASX:NXS) is a medical technology company developing innovative solutions to help improve surgical outcomes and reduce surgical site infections. The company's primary focus is the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health.
What is NXS known for?
Snapshot
Public AU
Ownership
2012
Year founded
102
Employees
New South Wales, Australia
Head office
1 of 38
AU Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Australia
Products and/or services of Next Science
- XBIO™ technology: Next Science's flagship product is its XBIO™ technology, a platform technology that can be used to develop a range of products to treat and prevent biofilm-based infections.
- XPERIENCE: Designed for use in cleansing and removal of debris, including microorganisms from wounds.
- BLASTX: Antimicrobial Wound Gel provides wound management by maintaining a moist wound environment, which is conducive to wound healing. While in place, the antimicrobial properties of the gel inhibit the growth of microorganisms in the product.
- SURGX: Sterile Antimicrobial Gel conforms to the postoperative wound. The gel provides a moist wound environment conducive to healing.
- Bactisure: Wound Lavage is used to remove debris, including microorganisms, from wounds using pulsed lavage. It is a clear, colourless and low-odour solution.
Next Science executive team
- Dr. Matthew Franco MynttiFounder & CTO
- Mr. Jon SwansonChief Strategy Officer
- Daniel CanonVice President of Operations
- Francoise DixonHead of Investor Relations
- Mr. Robert BellSenior Vice President of North American Sales
- Ms. Gillian Maria Nairn AGIA, B.A., L.L.B., L.L.M., MAICDCompany Secretary